Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging
about
Expression and purification of 15N- and 13C-isotope labeled 40-residue human Alzheimer's β-amyloid peptide for NMR-based structural analysisBACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor proteinThe genetics and neuropathology of Alzheimer's diseaseA window into the heterogeneity of human cerebrospinal fluid Aβ peptidesEndothelial LRP1 transports amyloid-β(1-42) across the blood-brain barrierOxidative stress in Alzheimer's and Parkinson's diseases: insights from the yeast Saccharomyces cerevisiaeBACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous systemPurification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR SpectroscopySelenomethionine incorporation into amyloid sequences regulates fibrillogenesis and toxicityNeuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease.Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease.NMR studies in aqueous solution fail to identify significant conformational differences between the monomeric forms of two Alzheimer peptides with widely different plaque-competence, A beta(1-40)(ox) and A beta(1-42)(ox).Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics.Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation.Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity.Systemic catabolism of Alzheimer's Abeta40 and Abeta42.Characterization of amyloid beta peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein.Formation of N-pyroglutamyl peptides from N-Glu and N-Gln precursors in Aplysia neurons.Fibrillar beta-amyloid peptide Abeta1-40 activates microglial proliferation via stimulating TNF-alpha release and H2O2 derived from NADPH oxidase: a cell culture studyThe turn formation at positions 22 and 23 in the 42-mer amyloid beta peptide: the emerging role in the pathogenesis of Alzheimer's disease.Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's diseaseIncreased expression of cholesterol transporter ABCA1 is highly correlated with severity of dementia in AD hippocampus.Small molecule microarrays enable the discovery of compounds that bind the Alzheimer's Aβ peptide and reduce its cytotoxicity.Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathiesThe Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's DiseaseThe role of cerebral amyloid beta accumulation in common forms of Alzheimer disease.Mammalian Metallothionein-3: New Functional and Structural InsightsNACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation.Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrierDespite its role in assembly, methionine 35 is not necessary for amyloid beta-protein toxicityMolecular identification of AMY, an Alzheimer disease amyloid-associated protein.Secretases as therapeutic targets for the treatment of Alzheimer's disease.Anti-11[E]-pyroglutamate-modified amyloid β antibodies cross-react with other pathological Aβ species: relevance for immunotherapy.Ensembles of protein termini and specific proteolytic signatures as candidate biomarkers of disease.The unique Alzheimer's β-amyloid triangular fibril has a cavity along the fibril axis under physiological conditions.Comparison of conventional ELISA with electrochemiluminescence technology for detection of amyloid-β in plasmaMetabotyping of docosahexaenoic acid - treated Alzheimer's disease cell modelSite-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluidThe ATP-binding cassette transporter-2 (ABCA2) increases endogenous amyloid precursor protein expression and Aβ fragment generation.Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease.
P2860
Q24633896-0727F7F6-7C3A-4868-B535-C318E1EFABD2Q24675964-4177616A-2AD9-4CDF-801C-79C05B0A3FA7Q26998097-C3EAB030-8968-443B-B56C-8867C25802BEQ27010785-6CF86A70-CADD-4F21-9B8A-36E33ABDBDD0Q27332086-5B26B029-A3F3-4508-97CE-FFDAFEC75EBEQ27692067-58579722-B717-473C-8950-08203FEEAF9FQ28480522-E92CD239-ECE9-440F-8BF3-0412B6274439Q28550062-21857A6C-EE1D-46A8-A7D8-5905A9CCB136Q30472712-BEE1A41C-4064-493C-9392-4F73D7ECC3B9Q30489052-B62E90BB-F171-4A90-9EB8-D20565698DDFQ30512697-AD20E381-CE86-4171-8128-BB32FA4AB9ACQ30666112-7CB909D2-93F7-41F3-B228-EE55DC5B48C8Q31047131-E210D443-AA77-4E8A-B53E-37E9CA8274F0Q31078434-F1B67ADB-7B1C-47B7-8DB8-23F47943BD38Q31100408-647C313F-ED38-4801-A494-BA133D8B1D98Q31107099-D55B211A-3490-43FE-AD84-B6AB765DB1F3Q31128115-61E0B95B-F670-4AF7-A47D-76801521E8C1Q31916641-7BC86567-08C3-420E-B095-5FCA4BC04DB6Q33256753-D5797244-0231-4F2E-A69B-A68AEA79E735Q33621850-BB065A39-6BA1-4FB2-93EA-144DB8EF0BE0Q33624303-FF1CA2BA-1244-4317-B932-B1A42417550DQ33679171-91A9FB55-A4AB-4B94-A13B-4F41D37ECCAAQ33742590-27F310D3-E031-4ED1-A608-67706F99D314Q33747695-98CB00CF-32A2-4127-BA37-E950D8499BF6Q33755982-E0DE355B-B365-4B04-9205-26E6287F11EEQ33768345-EBF468D4-1A84-411D-A655-7ADAA51357B8Q33838378-37385C0B-EB37-4CAC-B02E-76788270FE5DQ33888339-AAB3A028-7906-46C8-99DA-F90B96F59000Q33928434-DE20FF78-D944-4E65-A434-D53694225D19Q34012473-7605936D-80C7-4104-AC31-F6314064BF88Q34281060-FF8D11ED-BC4C-4FDE-97B2-2AD3A86AA94AQ34284352-61F5E508-0281-40CD-952A-2D5879F2AD23Q34348316-7372D6C0-94DB-40F8-9F9B-17C96CF06FC7Q34402330-61F3B6FA-3687-48EB-B05E-0F0328500C38Q34608660-A132CAE9-979A-453E-BE39-58AB9E181C29Q34786869-2AF5441D-7225-41DB-99F0-86FFF01B84C1Q35108713-A42022B2-2BBB-42E3-B1ED-2D8924140296Q35123119-CF950939-68C6-4F72-A234-33F984D66331Q35187927-FA985C7D-F909-4B9D-9386-29F3C7E02F5BQ35246412-1DC6229B-903C-40CF-9C28-C9417DC8AE19
P2860
Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Relative abundance of Alzheime ...... eimer disease and normal aging
@ast
Relative abundance of Alzheime ...... eimer disease and normal aging
@en
type
label
Relative abundance of Alzheime ...... eimer disease and normal aging
@ast
Relative abundance of Alzheime ...... eimer disease and normal aging
@en
prefLabel
Relative abundance of Alzheime ...... eimer disease and normal aging
@ast
Relative abundance of Alzheime ...... eimer disease and normal aging
@en
P2093
P2860
P356
P1476
Relative abundance of Alzheime ...... eimer disease and normal aging
@en
P2093
A Schierhorn
J Silberring
L Lannfelt
L O Tjernberg
P2860
P304
P356
10.1073/PNAS.91.18.8378
P407
P577
1994-08-01T00:00:00Z